<DOC>
	<DOC>NCT00740727</DOC>
	<brief_summary>Test whether Basic Life Support (BLS) providers can successfully place Enzymatically Augmented Subcutaneous Infusion (EASI) Access lines for subcutaneous infusion, and characterize intravascular absorption of EASI-administered (tracer-labelled) glucose (D5W).</brief_summary>
	<brief_title>EASI Access II --- Follow-up Study to the EASI Access Trial</brief_title>
	<detailed_description />
	<mesh_term>Dehydration</mesh_term>
	<criteria>Subjects will be at least 18 years of age and have none of the following conditions: pregnancy (negative urine pregnancy test to be performed before study participation), diabetes, or coagulopathic (including taking any anticoagulants); Subjects cannot be taking steroids or other immunosuppressants. Because of the potential for reduced hyaluronidase effectiveness, the study excludes patients taking more than 80 mg daily aspirin, as well as any patients taking ACTH, antihistamines, or estrogen other than in oral contraceptive preparations. Subjects will not be required to fast before the study, but will not allowed to eat or drink during the EASI infusion or the phlebotomy sampling time frame.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Disaster</keyword>
	<keyword>Mass casualty incident</keyword>
	<keyword>Prehospital</keyword>
	<keyword>Rehydration</keyword>
	<keyword>Intravascular access</keyword>
</DOC>